Abstract 3669: Autocrine interleukin/STAT3 signaling in breast implant-associated T cell anaplastic large cell lymphoma cell lines suggests a mechanism for tumor progression and effective therapy

Author(s):  
Connor H. Church ◽  
Melissa G. Lechner ◽  
Carolina Megiel ◽  
Rikki S. Bass ◽  
Sarah M. Russell ◽  
...  
2018 ◽  
Vol 65 (8) ◽  
pp. e27094 ◽  
Author(s):  
Sandra Hudson ◽  
Dongliang Wang ◽  
Frank Middleton ◽  
Barbara H. Nevaldine ◽  
Rana Naous ◽  
...  

Blood ◽  
2018 ◽  
Vol 132 (18) ◽  
pp. 1889-1898 ◽  
Author(s):  
Neha Mehta-Shah ◽  
Mark W. Clemens ◽  
Steven M. Horwitz

Abstract Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.


Author(s):  
Arianna Di Napoli ◽  
Daniele Greco ◽  
Giorgia Scafetta ◽  
Francesca Ascenzi ◽  
Alessandro Gulino ◽  
...  

Abstract Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is an uncommon peripheral T cell lymphoma usually presenting as a delayed peri-implant effusion. Chronic inflammation elicited by the implant has been implicated in its pathogenesis. Infection or implant rupture may also be responsible for late seromas. Cytomorphological examination coupled with CD30 immunostaining and eventual T-cell clonality assessment are essential for BI-ALCL diagnosis. However, some benign effusions may also contain an oligo/monoclonal expansion of CD30 + cells that can make the diagnosis challenging. Since cytokines are key mediators of inflammation, we applied a multiplexed immuno-based assay to BI-ALCL seromas and to different types of reactive seromas to look for a potential diagnostic BI-ALCL-associated cytokine profile. We found that BI-ALCL is characterized by a Th2-type cytokine milieu associated with significant high levels of IL-10, IL-13 and Eotaxin which discriminate BI-ALCL from all types of reactive seroma. Moreover, we found a cutoff of IL10/IL-6 ratio of 0.104 is associated with specificity of 100% and sensitivity of 83% in recognizing BI-ALCL effusions. This study identifies promising biomarkers for initial screening of late seromas that can facilitate early diagnosis of BI-ALCL.


Blood ◽  
2009 ◽  
Vol 114 (2) ◽  
pp. 360-370 ◽  
Author(s):  
Ping Shi ◽  
Raymond Lai ◽  
Quan Lin ◽  
Abid S. Iqbal ◽  
Leah C. Young ◽  
...  

Abstract Type I insulin-like growth factor receptor (IGF-IR) tyrosine kinase plays important roles in the pathogenesis of several malignancies. Although it promotes the growth of stimulated hematopoietic cells, a direct role of IGF-IR in malignant lymphoma has not been identified. Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+ ALCL) is a unique type of T-cell lymphoma. Approximately 85% of ALK+ ALCL cases harbor the translocation t(2;5)(p23;q35), which generates the chimeric oncogene NPM-ALK. In the present study, we explored a possible role of IGF-IR in ALK+ ALCL. Our results demonstrate that IGF-IR and IGF-I are widely expressed in ALK+ ALCL cell lines and primary tumors. Importantly, we identified novel reciprocal functional interactions between IGF-IR and NPM-ALK. Antagonism of IGF-IR decreased the viability, induced apoptosis and cell-cycle arrest, and decreased proliferation and colony formation of ALK+ ALCL cell lines. These effects could be explained by alterations of cell survival regulatory proteins downstream of IGF-IR signaling. Our findings improve current understanding of the biology of IGF-IR and NPM-ALK and have significant therapeutic implications as they identify IGF-IR signaling as a potential therapeutic target in ALK+ ALCL and possibly other types of malignant lymphoma.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3272-3272
Author(s):  
Tsuyoshi Nakamaki ◽  
Takashi Maeda ◽  
Hidetoshi Nakashima ◽  
Masamichi Hattori ◽  
Takako Usui ◽  
...  

Abstract Anaplastic large cell lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a aggressive T cell lymphoma. The 5-year survival rate of ALK-negative ALCL is less than those of ALK-positive ALCL. To address factor(s)involved in malignant progression of ALK-negative ALCL, we established two cell lines (N1, N2) at the different clinical stages from a 59-years-old male patient. He developed rapid progression and died five months after diagnosis. As shown in Table, N1 and N2 represent early and advanced stages of lymphoma phenotype, respectively. Both of them expressed CD2 and CD30 on the cell surface and showed identical TCR gene rearrangement. By Enzyme immunoassay, N2 showed constitutively higher activated, but not total, NFkappaB activity compared to N1. cDNA microroarray analysis compared two cell lines and revealed that expression of four chemokine receptors(CCR3, CCR6, CCR8, CXCR4) and six chemokines (CCL5, CCL8, CCL26, CXCL2, CXCL3, CXCL16) were down-regulated greater than two-fold in N2 compared to N1. Protein array analysis showed that N1, not N2, secreted significant amounts of CCL5, IL8 and VEGF in the culture medium. Moreover, conditioned medium from N1 (CMN1) showed cytotoxic effects on HL60 myeloid leukemia cell lines in culture,indicating CMN1 may contain additional cytotoxic factors not identified, because none of CCL5, IL8 and VEGF show cytotoxic effect on HL60 cells. cDNA microroarray analysis also demonstrated that six major histocompatibility complex (MHC) class II gene expression (HLA-DRβ5, HLA-DPα1, HLA-DPβ1, HLA-DMα, HLA-DMβ, HLA-DOβ) were down-regulated greater than two-fold in N2 compared to N1. Flow cytometric analysis also showed cell surface expression of HLA-DR were strongly positive for N1, but not detected for N2(Table). Fifteen genes were up-regulated greater than five-fold in N2 relative to N1. They include genes involved in apoptosis such as growth arrest -specific 2 and tumor protein p53 inducible nuclear protein 1. They also include recently cloned two genes involved in tumor progression, Neuronal cell death inducible putative kinase (41-fold) and Niban (10- fold). The differential expression of the two genes was also confirmed by real-time PCR analysis. Table Characteristics of ALCL cell lines ALCL cell line Stage of Disease Cell morphology Cell surface marker Doubling time (liquid culture) Colony formation (soft agar) total κ NF- B(pg/μg protein activated NF- κB(pg/μg protein *p=0.274 **p=0.003 N1 early round cell surface, single nucleolus CD2, CD30, HLADR 32.4 hrs 〈0.1% 298±25 * 565±91 ** N2 advanced irregular cell surface, multiple nucleoli CD2, CD30 22.8 hrs 10% 334±66 * 1067±96 ** Taken together,in addition to CD30-induced up-regulation of NFkappaB activity, present study suggests that following factors are possibly involved in the rapid progression of ALK-negative ALCL, (1) the loss of one or more of chemokine receptors involved in homing the ALCL cells to local lymphnode may trigger the potential of these cells to metastasize; (2) the loss of some types of chemokines and cytokines produced by ALCL cells which negatively regulate tumor progression through autocrine and paracrine manner; (3) the loss of one or more MHC class II expression may allow ALCL cells to escape immune system of host against tumors; (4)significant over-expression of gene(s) with oncogenic potential was induced after chemotherapy.


Pathobiology ◽  
1997 ◽  
Vol 65 (2) ◽  
pp. 83-90 ◽  
Author(s):  
Hans-Dieter Foss ◽  
Gudrun Demel ◽  
Ioannis Anagnostopoulos ◽  
Iguaracyra Araujo ◽  
Michael Hummel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document